Navigation Links
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Date:1/18/2012

OSAKA, Japan, January 18, 2012 /PRNewswire/ --

Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its 2011-2013 Mid-Range Plan (MRP).

The measures support both the execution of the company's strategy and the integration targets announced last year. They would also bring further efficiencies to the organization to sustain medium and long-term growth targets starting in fiscal 2015. The company will align Nycomed's former operation structures and processes with the Takeda global headquarters in Japan and the newly defined organizations of the Chief Commercial Officer - which is headquartered in Zurich, Switzerland - and Chief Medical & Scientific Officer - which is headquartered in Deerfield, Illinois - and its expanded affiliate network worldwide.

"The combination of Takeda and Nycomed, which we acquired on September 30, 2011, brought together Takeda's strong presence in the Japanese and U.S. markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets," said Yasuchika Hasegawa, President & CEO, Takeda Pharmaceutical Company Limited. "While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward."

Takeda will secure a sustainable future by maximizing the synergies of the steady integration of Takeda and Nycomed, such as the sales expansion of Takeda's product pipeline utilizing Nycomed's strong sales platforms in Europe and emerging countries.

To meet the needs of the market, Takeda will also shift from a prod
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
2. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
3. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
5. Takeda Completes Acquisition and Names New CEO of Nycomed
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
9. Takeda to Acquire Nycomed
10. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
11. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... , President and Chief Executive Officer, will present a ... Conference. Anthera will present at 4:30PM ... in New York City . ... is a biopharmaceutical company focused on developing and commercializing ...
(Date:11/22/2014)... de noviembre de 2014  BioClinica®, Inc., un ... y tecnologías eClinical, ha indicado un aumento de ... para el seguimiento basado en el riesgo en ... concepto del seguimiento basado en el riesgo más ... de seguimiento o cambio de los métodos de ...
(Date:11/22/2014)... 2014 Research and Markets  has announced the ... Report, 2014-2017" report to their offering. ... recombinant protein drug market has been expanding rapidly owing ... the like. During 2005-2013, sales of recombinant protein drugs ... of 19.1%, and it is projected that ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
... Studies in Mice Show Reduction of Enzyme ... -- Amicus,Therapeutics, a biopharmaceutical company developing,small-molecule, orally ... genetic diseases, announced today that the,Company will ... AT1001), Amicus' compound in development for the,treatment ...
... 2007 - Avid,Radiopharmaceuticals, Inc. (Avid), a product-focused ... the first,results from a clinical study of ... tomography (PET) imaging,of amyloid plaques in patients ... from Austin Hospital of,Melbourne, a leading investigator ...
Cached Medicine Technology:Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 2Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 3Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 2Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 3Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 4
(Date:11/24/2014)... Houston, TX (PRWEB) November 24, 2014 ... in all of the wrong ingredients. Consistently consuming a ... body to develop stores of excess fat that typically ... health problems and rearing its ugly head in the ... , When dieters make the decision to rid ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
(Date:11/24/2014)... Diego, California (PRWEB) November 24, 2014 Dr. ... San Diego Fertility Center, recently appeared on NBC to discuss ... option. Egg freezing has been trending in the news recently, ... this expensive procedure for women. , “[The companies] ... women who are on a career hot path.” Says Dr. ...
(Date:11/23/2014)... November 24, 2014 The clinical ... 2014" provides data on the Aspergillosis clinical trial ... relating to the clinical trials on Aspergillosis. It ... their recruitment status as per the site of ... a preliminary coverage of disease clinical trials by ...
(Date:11/23/2014)... 24, 2014 For the coming special ... has launched a great promotion for many products, especially ... can get the best choice with amazing discounts, up ... Tidebuy.com. , It is easy to buy colored ... that, this selection is also famous for delicate craftsmanship, ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
... now infarct size has only been measured as part of ... being that the reference method of gadolinium based contrast agents ... to perform, and can only be undertaken by imaging specialists," ... Padua, Italy. "The advantages of STE over MRI is that ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- Working ... may also increase your risk of developing type 2 diabetes, new ... found that those who worked rotating night shifts were more likely ... the longer that they worked a rotating shift schedule, the greater ...
... TX - Accelerated partial breast irradiation (APBI) brachytherapy, ... popular as a treatment choice for women with ... of later mastectomy, increased radiation-related toxicities and post-operative ... according to researchers from The University of Texas ...
... Denise Mann HealthDay Reporter , TUESDAY, Dec. 6 ... for preterm birth as early as 23 weeks during their ... reduce the baby,s risk of serious developmental issues, including brain ... the Dec. 7 issue of the Journal of the ...
... , TUESDAY, Dec. 6 (HealthDay News) -- U.S. ... remove controversial, unapproved and illegally labeled HCG weight loss products ... a hormone made by the human placenta and found in ... in conjunction with an extremely low-calorie diet -- as low ...
... Reinberg HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay ... with hormone therapy do not appear to be at increased ... new review of evidence. Hormone therapy called "androgen ... previous studies found that the therapy might increase the risk ...
Cached Medicine News:Health News:Echocardiography offers the future for infarct size quantification 2Health News:Echocardiography offers the future for infarct size quantification 3Health News:Echocardiography offers the future for infarct size quantification 4Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 3Health News:Steroids May Boost Survival for Very Preemie Babies 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: